Foundayo vs the Wegovy Pill: Which Oral GLP-1 Wins?
Two once-daily GLP-1 pills, both new to the market in 2026. One has timing rules; the other does not. Here is the honest comparison nobody else has published.
The short answer#
The differences that matter#
| Foundayo (orforglipron) | Wegovy | |
|---|---|---|
| Molecule type | Small molecule (orforglipron) | Peptide (semaglutide) |
| Timing rules | None — any time, with or without food or water | Empty stomach, specific water volume, wait before eating |
| Approved | April 2026 | December 2025 (oral form) |
| Entry price | $149/mo (0.8 mg) | $149/mo (1.5 mg) |
| Top dose price | $349/mo | $299/mo |
| Evidence maturity | Newer — long-term real-world data still accumulating | Semaglutide has years of trial and real-world data |
| Medicare Bridge | Included | Included |
Cheapest channels for each, right now#
Sources#
Run your own numbers with the GLP-1 cost calculator, check whether you're overpaying with the price checker, or see every comparison we publish.
Common questions#
Foundayo vs the Wegovy Pill?#
Foundayo's practical advantage is convenience: as a small molecule it needs no food-and-water choreography, while oral semaglutide does. Wegovy's pill has the longer evidence trail behind its molecule and matching entry pricing. Both start at $149 a month at their manufacturer channels, so for most shoppers this comes down to timing rules versus track record.
Comparisons of approved uses, mechanisms, and published trial averages — not medical advice, and averages are not individuals. Which medication suits you is a decision for you and a licensed clinician. Prices carry the verification dates shown. No link on this page earns us a commission; comparisons are computed from data, never compensation — disclosure.